December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
1 citations
,
August 2025 GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.
2 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib improves hair regrowth in alopecia areata over 24 months.
August 2025 in “JAAD International” Bicalutamide may reduce hair shedding in women but needs longer trials to confirm its effectiveness.
88 citations
,
July 2009 in “Experimental and Clinical Endocrinology & Diabetes”
June 2017 in “Poster presentations” All four treatments for early rheumatoid arthritis had similar safety profiles.
March 2024 in “Poster presentations” Anifrolumab improves quality of life and reduces steroid use in SLE patients.
232 citations
,
June 1975 in “Journal of Steroid Biochemistry” Cyproterone acetate is effective for acne but less so for hirsutism and alopecia, with some side effects and quick menstrual cycle recovery after treatment.
January 2007 in “Journal of The American Academy of Dermatology” Propylthiouracil, a thyroid medication, can cause skin blood clots and immune-related blood vessel inflammation.
31 citations
,
July 2017 in “Journal of the American Academy of Dermatology” Apremilast improved symptoms in patients with severe skin conditions.
May 2017 in “Journal of The American Academy of Dermatology” A woman with a skin disorder was found to have hepatitis C, which may be linked, and was safely treated with methotrexate.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
2 citations
,
January 2010 in “Side effects of drugs annual” Dermatological drugs and cosmetics can cause serious side effects like cancer, allergies, and heart issues.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
1 citations
,
January 2024 in “Curēus” Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
December 2025 in “The Journal of Dermatology” Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.
March 2025 in “JAAD reviews.” Bicalutamide can reduce female pattern hair loss, especially in those with certain conditions, but has limited effects on other hair loss types.
2 citations
,
April 2021 in “The Egyptian Journal of Histology” Platelet-rich plasma helps protect and improve ovarian function in rats treated with cyclophosphamide.
July 2025 in “Journal of Investigative Dermatology” IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
February 2026 in “International Journal of Dermatology” Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
Combining pentoxifylline with corticosteroids improves alopecia areata treatment.
October 2023 in “European journal of dermatology/EJD. European journal of dermatology” Injectable platelet-rich fibrin can safely and effectively treat melasma.
5 citations
,
November 2023 in “The Journal of Dermatology” Anifrolumab effectively improved symptoms and reduced steroid use in Japanese patients with systemic lupus erythematosus.
18 citations
,
September 1979 in “DMW - Deutsche Medizinische Wochenschrift” Diane is effective for treating acne, seborrhoea, androgenic alopecia, and mild hirsutism in women.
September 2022 in “Journal of Ayub Medical College Abbottabad” Steroid injections are more effective than platelet rich plasma for treating patchy hair loss.
5 citations
,
January 2017 in “Chalmers Publication Library (Chalmers University of Technology)” Cubosomes enhance antimicrobial peptide stability and effectiveness.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.